Doximity stock sinks aftermarket after FY guidance slashed

Aug. 04, 2022 5:29 PM ETDoximity, Inc. (DOCS)By: Jessica Kuruthukulangara, SA News Editor9 Comments

Healthcare business graph data and growth, Insurance Healthcare. Doctor analyzing medical of business report and medical examination with network connection on laptop screen.

ipopba

  • Doximity (NYSE:DOCS) stock sank 17% postmarket on Thursday after the digital platform for U.S medical professionals slashed its FY guidance in its Q1 earnings report.
  • DOCS expects FY revenue of $424M-$432M, well below consensus estimate of $455.92M. Its prior outlook was $454M-$458M.
  • FY adj. EBITDA is projected to be $178M-$186M vs. previous guidance of $192M-$196M.
  • DOCS expects Q2 revenue of $99.5M-$100.5M, lower than consensus estimate of $105.03M.
  • Q2 adj. EBITDA is estimated to be $40M-$41M vs. $32.8M in Q2 2022.
  • DOCS reported Q1 adj. EPS of $0.14 vs. $0.11 in Q1 2022.
  • Revenue rose 25% Y/Y to $90.6M.
  • Adj. EBITDA grew 8% to $33.5M, representing adj. EBITDA margins of 37% vs. 43% in Q1 2022.
  • Shares of DOCS have fallen ~22% YTD.

Recommended For You

Comments (9)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.